Publications by authors named "Ana Maria Pello-Lazaro"
Article Synopsis
- ATTR-CM is increasingly common, and the medication diflunisal has been shown to stabilize certain markers related to heart function, but its effects on heart structure changes over time need further research.
- The AMILCA-DIFLU study involved 12 ATTR-CM patients, with only nine completing the year-long treatment, and found that diflunisal did not significantly improve heart disease status, although there was a slight trend toward stabilization in some heart-related measurements.
- Despite showing some potentially positive trends, diflunisal was well tolerated overall, with only a minor increase in renal dysfunction that didn’t lead to any serious complications or the need to stop treatment.
Heart failure (HF) is a highly prevalent syndrome in elderly subjects. Currently, multiple drugs have shown clinical benefits in patients with HF and reduced ejection fraction (HFrEF). However, evidence is scarce in elderly patients (beyond 75 years old), even more so for the latest drugs, such as angiotensin receptor-neprilysin inhibitors (ARNIs).
View Article and Find Full Text PDF(1) Background: The validation of new lines of therapy for the elderly is required due to the progressive ageing of the world population and scarce evidence in elderly patients with HF with reduced ejection fraction (HFrEF). The purpose of our study is to analyze the effect of SGLT2 inhibitors (SGLT2i) in this subgroup of patients. (2) Methods: A single-center, real-world observational study was performed.
View Article and Find Full Text PDFAims: Heart failure (HF) with reduced left ventricle ejection fraction (LVEF) is an entity with poor prognosis characterized by decompensations. Bioelectrical impedance analysis (BIA) is used to assess volume overload (VO) and may be useful to identify apparently stable HF outpatients at risk of decompensation. The aim of this study is to analyse whether VO assessed by BIA is associated with worsening heart failure (WHF) in stable outpatients with HF and reduced LVEF (HFrEF).
View Article and Find Full Text PDFArticle Synopsis
- This study investigates the relationship between mineral metabolism (MM) and cardiac rehabilitation (CR) in patients who experienced acute coronary syndrome (ACS).
- A total of 58 patients undergoing CR were compared with 116 control patients, revealing significant differences in hypertension prevalence and medication use.
- Results showed that after six months, klotho levels increased significantly in CR patients, while controls experienced a decrease, suggesting a potential positive effect of CR on MM that warrants further exploration.
The pathophysiological mechanisms underlying Myocardial Infarction with Non-Obstructive Coronary Artery Disease (MINOCA) are still under debate. Lipoprotein (a) [Lp(a)] has proinflammatory and prothrombotic actions and has been involved in the pathogenesis of atherosclerosis. However, no previous studies have linked Lp(a) levels with the probability of developing MINOCA.
View Article and Find Full Text PDFBackground: Parathormone (PTH) is a component of the Mineral Metabolism (MM) system that has been shown recently to add prognostic value in pts. with stable coronary artery disease (SCAD) and average renal function. However, the influence of renal function on the prognostic role of PTH in pts.
View Article and Find Full Text PDFInflammation has long been known to play a role in atherogenesis and plaque complication, as well as in some drugs used in therapy for atherosclerotic disease, such as statins, acetylsalicylic acid, and modulators of the renin-angiotensin system, which also have anti-inflammatory effects. Furthermore, inflammatory biomarkers have been demonstrated to predict the incidence of cardiovascular events. In spite of this, and with the exception of acetylsalicylic acid, non-steroidal anti-inflammatory drugs are unable to decrease the incidence of cardiovascular events and may even be harmful to the cardiovascular system.
View Article and Find Full Text PDFAims: As evidenced by scintigraphy imaging, the prevalence of transthyretin (TTR) cardiac amyloidosis in heart failure patients with preserved ejection fraction (HFpEF) and left ventricular hypertrophy (LVH) ranges between 13% and 19%. The natural evolution of cardiac amyloidosis begins with the deposition of amyloid material in the myocardium, with LVH ensuing at later stages. With current imaging modalities, it is possible to detect TTR cardiac amyloidosis before the hypertrophic stage.
View Article and Find Full Text PDFClinical data indicate that patients with C-reactive protein (CRP) levels higher than 2 mg per liter suffer from persistent inflammation, which is associated with high risk of cardiovascular disease (CVD). We determined whether a panel of biomarkers associated with CVD could predict recurrent events in patients with low or persistent inflammation and coronary artery disease (CAD). We followed 917 patients with CAD (median 4.
View Article and Find Full Text PDFArticle Synopsis
- Statins may have anti-inflammatory benefits that could lower mortality rates after respiratory viral infections (RVI).
- A study involving 448 adult patients found that those using statins had a significant mortality benefit over non-users during a 1-year follow-up.
- The outcomes were particularly notable for non-cardiovascular mortality, suggesting chronic statin use could be advantageous after an RVI, warranting further research into its effects.
Our purpose was to assess a possible association of inflammatory, lipid and mineral metabolism biomarkers with coronary artery ectasia (CAE) and to determine a possible association of this with acute atherotrombotic events (AAT). We studied 270 patients who underwent coronary angiography during an acute coronary syndrome 6 months before. Plasma levels of several biomarkers were assessed, and patients were followed during a median of 5.
View Article and Find Full Text PDFArticle Synopsis
- * Current research includes numerous clinical trials aimed at finding antivirals and immunomodulators, but new therapies focused on the cardiovascular system, such as using ACE inhibitors and angiotensin receptor blockers, may effectively lessen disease severity.
- * Investigating the non-canonical pathways of the renin-angiotensin-aldosterone system (RAAS) could provide insights into reducing cardiovascular complications, while genetic factors and sex hormones could also play a role in the body’s response to COVID-19.
It is essential to study the factors associated with the evolution of aortic stenosis progression (ASP) to develop therapies that could reduce it. We studied 283 patients 6 months after acute coronary syndrome (ACS). ASP was defined as an increase in the maximum aortic velocity of at least 0.
View Article and Find Full Text PDFBackground: Heart failure (HF) with preserved ejection fraction (HFpEF) and monoclonal gammopathy of uncertain significance (MGUS) are two entities that share pathophysiological mechanisms. The aim herein, was to assess the prevalence of MGUS in patients with HFpEF and no left ventricular (LV) hypertrophy, as well as its association with a pre-specified clinical endpoint at 12 months.
Methods: The present study prospectively enrolled 69 patients admitted with HF, with ejection fraction ≥ 50%, and LV wall thickness < 12 mm.
Objectives: Proton-pump inhibitors (PPIs) seem to increase the incidence of cardiovascular events in patients with coronary artery disease (CAD), mainly in those using clopidogrel. We analysed the impact of PPIs on the prognosis of patients with stable CAD.
Methods: We followed 706 patients with CAD.
Background: Beta-blockers (BBs) remain underused in elderly patients with reduced ejection fraction (REF). Our aim was to determine the prognostic impact of different doses of BB in this setting.
Methods And Results: A single-center observational study was conducted.